Our observation of lowered MAP3K11 expression levels with reduced genetic liability to AD risk, in conjunction with in vitro studies suggesting MLK3 modulation in reducing amyloid-β induced toxicity32, place MLK3 inhibitors in a pertinent context with AD. This evidence concerns the gene MAP3K11 and Alzheimer disease.